摘要
为探讨广州地区丙型肝炎病毒（ＨＣＶ）感染的基因型及其与疾病程度、感染途径和干扰素疗效的关系，作者应用分型ＰＣＲ技术对１５６例抗－ＨＣＶ阳性患者血清ＨＣＶＲＮＡ进行分型检测，并分析不同程度肝病及不同感染途径ＨＣＶ基因型分布，且对５１例经干扰素治疗的慢性丙肝作分型评价。结果１２４例ＨＣＶＲＮＡ阳性中，Ⅱ型占９０．３％（１１２例），Ⅲ型占８．１％（１０例），Ⅱ／Ⅲ型混合感染占１．６％（２例），未检出Ⅰ、Ⅳ型，说明广州地区ＨＣＶ感染以Ⅱ型为主；不同程度肝病及不同感染途径之间ＨＣＶ基因型构成比无明显差异，表明基因型与疾病严重程度及感染途径关系不大；干扰素治疗病例，ＨＣＶ－Ⅱ、Ⅲ型感染的总应答数、完全应答数及部分应答数分别为１８／４１，１１／４１，７／４１和８／１０，６／１０，２／１０，提示Ⅲ型感染疗效较好，ＨＣＶ基因型似可作为选择干扰素治疗病例及判断疗效的参考指标，但是由于观察的Ⅲ型病例数较少，需积累更多的资料才能作出更客观的结论。
The sera from 156 anti HCV positive patients were typed by PCR with core region type specific primers,and the distribution of HCV genotypes among different kinds of liver disease and different HCV infectious routes was compared.Also,the effect of interferon therapy in 51 chronic hepatits C patients with different genotypes was estimated.It was shown that,of 124 patients with positive PCR product,90 3%(112) were infected with HCV Ⅱ,8 1%(10) were infected with HCV Ⅲ,and the other 1 6%(2) with HCV Ⅱ/Ⅲ coinfection.There was no significant difference in HCV genotype distribution among various liver deseases with different severity and among different HCV infectious routes.The number of cases with total response,complete response and partial response to interferon in patients with HCV Ⅱ,HCV Ⅲ infection were 18/41,11/41,7/41 and 8/10,6/10,2/10,respectively.The response rate in HCV Ⅲ infection was higher than that in HCV Ⅱ infection.Our results suggest that HCV Ⅱ is the most prevalent type of HCV infection in Guangzhou area.There is no evident relationship between HCV genotypes and severity of liver disease,and between HCV genotypes and different transmission routes.The response to interferon may vary according to the difference of HCV genotype,and the genotype of HCV may serve as a referencing index of predicting the response to interferon.But,to get a more objective conclusion to this,the observation of more interferon treated patients is needed.
出处
《中华微生物学和免疫学杂志》
CAS
CSCD
北大核心
1997年第2期92-95,共4页
Chinese Journal of Microbiology and Immunology
基金
广东省重点科技攻关项目
关键词
丙型肝炎病毒
基因型
感染途径
干扰素
病理学
Hepatitis C virus
Genotype
Polymerase chain reaction
Hepatitis C
Interferons
